camzyos (mavacamten) 2.5mg capsule

Camzyos (Mavacamten) works by modulating the function of cardiac myosin, which plays a crucial role in heart muscle contraction.

Mechanism of Action:

1. Myosin Inhibition: Mavacamten selectively binds to and inhibits cardiac myosin, the motor protein responsible for heart muscle contraction. By reducing myosin activity, it decreases the force of the heart’s contractions.
2. Reduction of Hypercontractility: In hypertrophic cardiomyopathy, the heart muscle contracts too forcefully, leading to thickening of the heart walls, obstructing blood flow, and increasing the risk of heart failure. Camzyos reduces this hypercontractility, thereby alleviating the excessive thickening of the heart muscle.
3. Improvement of Cardiac Output: By lowering the excessive contractile force, Camzyos helps improve overall cardiac function, allowing for better blood flow and reducing the symptoms of HCM such as shortness of breath, chest pain, and fatigue.
4. Potential Remodeling Effects: Long-term use of Camzyos may also contribute to positive remodeling of the heart muscle, potentially reducing the thickening over time.

Camzyos offers a targeted approach to treating HCM by addressing the underlying cause of hypercontractility, rather than just managing the symptoms.

Side Effects

While Camzyos is generally well-tolerated, some patients may experience side effects.

Common Side Effects:

• Dizziness: Some patients may feel lightheaded or dizzy, particularly when standing up quickly.
• Fatigue: Unusual tiredness or weakness is commonly reported.
• Headache: Mild to moderate headaches may occur during treatment.
• Nausea: Some individuals may experience nausea after taking the medication.
• Hypotension: Lowering of blood pressure can occur, leading to symptoms such as lightheadedness or fainting.

Serious Side Effects:

• Heart Failure: Due to its effects on heart contractility, there is a potential risk of heart failure, particularly if the dosage is not carefully managed.
• Arrhythmias: Abnormal heart rhythms may occur, requiring close monitoring by a healthcare provider.
• Cardiovascular Collapse: In rare cases, excessive reduction in heart muscle contractility can lead to severe cardiovascular complications.

Patients are advised to report any severe or unusual side effects to their healthcare provider immediately.

Indications

Camzyos is specifically indicated for the treatment of certain heart conditions.

Approved Indications:

1. Hypertrophic Cardiomyopathy (HCM): Camzyos is primarily indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. It is used to reduce symptoms such as shortness of breath, chest pain, and fainting, which are common in patients with HCM.
2. Symptomatic Relief in HCM: Camzyos is also indicated for patients who have persistent symptoms despite taking other heart medications, providing an additional treatment option for managing the condition.

Contraindications

Camzyos may not be suitable for all patients, particularly those with certain pre-existing conditions or who are taking specific medications.

Contraindications:

1. Hypersensitivity to Mavacamten: Patients with a known allergy to mavacamten or any other components of Camzyos should avoid this medication.
2. Advanced Heart Failure: Patients with severe heart failure (NYHA Class IV) may not be suitable candidates for Camzyos due to the risk of further reducing heart muscle contractility.
3. Concomitant Use of Certain Medications: Camzyos should not be used concurrently with strong CYP2C19 or CYP3A4 inhibitors or inducers, as these can significantly alter the metabolism of mavacamten, leading to adverse effects.
4. Severe Liver or Kidney Impairment: Patients with severe hepatic or renal impairment may need to avoid or adjust the dosage of Camzyos due to altered drug metabolism and excretion.

Price in Different Countries

The cost of Camzyos can vary significantly depending on the country and healthcare system. Below is a table with the estimated price of Camzyos in various countries.

Country	Price (Per Month Supply)	Reference
United States	$10,000 – $15,000	GoodRx
United Kingdom	£7,500 – £10,000	NHS UK
Canada	CAD $13,000 – $17,000	DrugBank
Australia	AUD $14,000 – $18,000	PBS Australia
India	INR ₹7,50,000 – ₹10,00,000	MedIndia

Top 5 Global Brands

While Camzyos is a specific brand of mavacamten, other pharmaceutical companies are also known for their leadership in cardiovascular therapeutics.

1. Bristol-Myers Squibb (BMS)

• BMS is the developer of Camzyos and a leader in cardiovascular disease treatment, offering innovative solutions for heart conditions.

2. Novartis

• Novartis has a strong portfolio in cardiovascular medicines, including drugs like Entresto for heart failure.

3. Pfizer

• Pfizer is known for its cardiovascular treatments, including medications like Lipitor for cholesterol management.

4. AstraZeneca

• AstraZeneca offers a wide range of cardiovascular therapies, including Brilinta for the prevention of heart attacks.

5. Sanofi

• Sanofi is a major player in the cardiovascular field, with products like Praluent for cholesterol management.